Literature DB >> 22452524

Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study.

M F B Braga1, A Casanova, H Teoh, H C Gerstein, D H Fitchett, G Honos, P A McFarlane, E Ur, J-F Yale, A Langer, S G Goodman, L A Leiter.   

Abstract

AIMS: To prospectively evaluate diabetes management in the primary care setting and explore factors related to guideline-recommended triple target achievement [blood pressure (BP) ≤ 130/80 mmHg, A1C ≤ 7% and low-density lipoprotein (LDL)-cholesterol < 2.5 mmol/l].
METHODS: Baseline, 6 and 12 month data on clinical and laboratory parameters were measured in 3002 patients with type 2 diabetes enrolled as part of a prospective quality enhancement research initiative in Canada. A generalised estimating equation model was fitted to assess variables associated with triple target achievement.
RESULTS: At baseline, 54%, 53% and 64% of patients, respectively, had BP, A1C and LDL-cholesterol at target; all three goals were met by 19% of patients. The percentage of individuals achieving these targets significantly increased during the study [60%, 57%, 76% and 26%, respectively, at the final visit, p < 0.0001 except for A1C, p = 0.27]. A much smaller proportion of patients had adequate control during the entire study period [30%, 39%, 53% and 7%, respectively]. In multivariable analysis, women, patients younger than 65 years and patients of Afro-Canadian origin were less likely to achieve the triple target. DISCUSSION: As part of a quality enhancement research initiative, we observed important improvements in the attainment of guidelines-recommended targets in patients with type 2 diabetes followed for a 12-month period in the primary care setting; however, many individuals still failed to achieve and especially maintain optimal goals for therapy, particularly the triple target. Results of the multivariable analysis reinforce the need to address barriers to improve diabetes care, particularly in more susceptible groups.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22452524     DOI: 10.1111/j.1742-1241.2012.02894.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  22 in total

Review 1.  Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.

Authors:  Damayanthi Devineni; David Polidori
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

2.  Current status of treatment of type 2 diabetes mellitus in Ningbo, China.

Authors:  Tianmeng Yang; Rongjiong Zheng; Qingmei Chen; Yushan Mao
Journal:  J Clin Lab Anal       Date:  2018-11-21       Impact factor: 2.352

Review 3.  Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

Authors:  Sreeneeranj Kasichayanula; Xiaoni Liu; Frank Lacreta; Steven C Griffen; David W Boulton
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

4.  Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Authors:  Ottavio Giampietro; Chiara Giampietro; Luca Della Bartola; Maria Chiara Masoni; Elena Matteucci
Journal:  Drug Des Devel Ther       Date:  2013-02-14       Impact factor: 4.162

5.  Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry.

Authors:  Roland E Schmieder; Anselm K Gitt; Cornelia Koch; Peter Bramlage; Taoufik Ouarrak; Diethelm Tschöpe
Journal:  BMC Endocr Disord       Date:  2015-05-02       Impact factor: 2.763

6.  Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Authors:  Martin Ridderstråle; Robbyna Svaerd; Cordula Zeller; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-09-05       Impact factor: 9.951

Review 7.  Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia.

Authors:  Guido Gembillo; Ylenia Ingrasciotta; Salvatore Crisafulli; Nicoletta Luxi; Rossella Siligato; Domenico Santoro; Gianluca Trifirò
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

8.  Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE.

Authors:  Anselm K Gitt; Roland E Schmieder; Eva Duetting; Peter Bramlage; Steffen Schneider; Diethelm Tschöpe
Journal:  Cardiovasc Diabetol       Date:  2012-12-05       Impact factor: 9.951

9.  Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.

Authors:  Zdravko Kamenov
Journal:  Diabetes Ther       Date:  2014-09-23       Impact factor: 2.945

10.  Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial.

Authors:  Lene Munch; Birgitte Bennich; Anne B Arreskov; Dorthe Overgaard; Hanne Konradsen; Filip K Knop; Tina Vilsbøll; Michael E Røder
Journal:  Trials       Date:  2016-06-04       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.